• Je něco špatně v tomto záznamu ?

GAD antibodies in T1D and LADA--relations to age, BMI, c-peptide, IA-2 and HLA-DRB1*03 and DRB1*04 alleles

P. Weber, P. Ambrosova, P. Canov, D. Weberova, P. Kuklinek, H. Meluzinova, H. Matejovska-Kubesova, P. Cejkova, K. Bielakova, M. Cerna,

. 2011 ; 24 (2) : 312-8.

Jazyk angličtina Země Rusko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc12028034
E-zdroje Online Plný text

NLK ProQuest Central od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2011-01-01 do Před 1 rokem

The determination of GADA may be useful for clinical classification of diabetes mellitus (DM) in clinically unclear cases. This GADA positivity may persist in any diabetics Type 1 Diabetes Mellitus (T1D) with an onset in adulthood and Late Autoimmune Diabetes of Adults (LADA) many years after appearance of DM. The study was aimed at comparing the levels of GADA between both diabetic subsets with their clinical parameters, age of onset DM, period of insulin need, body mass index, HbA1C, fasting and postprandial C-peptide, risky HLA-DRB1* alleles, occurrence of micro- and macrovascular diabetic complications. Further analysis of GADA titers in different time consequences to the development of DM and relations to IA-2 were made. In the study, we included 130 diabetics with an onset of diabetes (T1D or LADA) 35+ y. who were hospitalized and afterwards long-term observed in the diabetological outpatient department. Out of this number there were 62 men and 68 women of the average age 65.5 +/- 14.0 y. (range 35-93 y.). 54 were assessed as the T1D patients and 76 as the LADA ones. Patients of the T1D subgroup were GADA positive 22 times and of the LADA subgroup 21 times. LADA 2 patients that were GADA negative were more obese than GADA positive LADA diabetics (p < 0.01). Also postprandial C-peptide was higher in LADA patients GADA negative (p < 0.05). Other clinical characteristics were without statistically significant differences. We found in our diabetic patients a relation between alleles HLA-DRB1*03 and particularly combination with HLA-DRB1*04 with positive GADA levels. In the GADA negative group obesity, coronary heart disease, hypertension, syndrome of diabetic foot and dyslipidaemia appeared more frequently (OR = 2.8; 3.1; 6.2 and 2.4). We found no significant differences in observed parameters--comparison GADA positivity and negativity according to the duration of DM. GADA positive were even 10 y. duration 16 times and after 20 y. even 6 times. Recent DM had positive GADA in 11 cases and 13 cases of recent DM had GADA negative. IA-2 antibodies were positive (> 1.0 U/ml) 18 times altogether and always with positive GADA, but only 7 times in recent DM. The presence of elevated GADA identifies patients unequivocally suitable for early insulin therapy. Our observations and experiences confirm that GADA can be found increased after more than 10-20 years duration of DM, although in decreasing trend.

000      
00000naa a2200000 a 4500
001      
bmc12028034
003      
CZ-PrNML
005      
20200318175549.0
007      
ta
008      
120817s2011 ru f 000 0#eng||
009      
AR
035    __
$a (PubMed)21957594
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ru
100    1_
$a Weber, Pavel $7 xx0102175 $u Department of Internal Medicine, Geriatrics and Practical Medicine, Faculty Hospital and Masaryk University, Brno, Czech Republic. p.weber@fnbrno.cz
245    10
$a GAD antibodies in T1D and LADA--relations to age, BMI, c-peptide, IA-2 and HLA-DRB1*03 and DRB1*04 alleles / $c P. Weber, P. Ambrosova, P. Canov, D. Weberova, P. Kuklinek, H. Meluzinova, H. Matejovska-Kubesova, P. Cejkova, K. Bielakova, M. Cerna,
520    9_
$a The determination of GADA may be useful for clinical classification of diabetes mellitus (DM) in clinically unclear cases. This GADA positivity may persist in any diabetics Type 1 Diabetes Mellitus (T1D) with an onset in adulthood and Late Autoimmune Diabetes of Adults (LADA) many years after appearance of DM. The study was aimed at comparing the levels of GADA between both diabetic subsets with their clinical parameters, age of onset DM, period of insulin need, body mass index, HbA1C, fasting and postprandial C-peptide, risky HLA-DRB1* alleles, occurrence of micro- and macrovascular diabetic complications. Further analysis of GADA titers in different time consequences to the development of DM and relations to IA-2 were made. In the study, we included 130 diabetics with an onset of diabetes (T1D or LADA) 35+ y. who were hospitalized and afterwards long-term observed in the diabetological outpatient department. Out of this number there were 62 men and 68 women of the average age 65.5 +/- 14.0 y. (range 35-93 y.). 54 were assessed as the T1D patients and 76 as the LADA ones. Patients of the T1D subgroup were GADA positive 22 times and of the LADA subgroup 21 times. LADA 2 patients that were GADA negative were more obese than GADA positive LADA diabetics (p < 0.01). Also postprandial C-peptide was higher in LADA patients GADA negative (p < 0.05). Other clinical characteristics were without statistically significant differences. We found in our diabetic patients a relation between alleles HLA-DRB1*03 and particularly combination with HLA-DRB1*04 with positive GADA levels. In the GADA negative group obesity, coronary heart disease, hypertension, syndrome of diabetic foot and dyslipidaemia appeared more frequently (OR = 2.8; 3.1; 6.2 and 2.4). We found no significant differences in observed parameters--comparison GADA positivity and negativity according to the duration of DM. GADA positive were even 10 y. duration 16 times and after 20 y. even 6 times. Recent DM had positive GADA in 11 cases and 13 cases of recent DM had GADA negative. IA-2 antibodies were positive (> 1.0 U/ml) 18 times altogether and always with positive GADA, but only 7 times in recent DM. The presence of elevated GADA identifies patients unequivocally suitable for early insulin therapy. Our observations and experiences confirm that GADA can be found increased after more than 10-20 years duration of DM, although in decreasing trend.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a alely $7 D000483
650    _2
$a autoprotilátky $x krev $7 D001323
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a C-peptid $x krev $7 D002096
650    _2
$a diabetes mellitus 1. typu $x krev $x genetika $x imunologie $7 D003922
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamát dekarboxyláza $x imunologie $7 D005968
650    _2
$a HLA-DR antigeny $x genetika $7 D006684
650    _2
$a HLA-DRB1 řetězec $7 D059811
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a tyrosinfosfatasy receptorového typu, třída 8 $x imunologie $7 D054635
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ambrosova, P $7 gn_A_00005378
700    1_
$a Canov, P
700    1_
$a Prudius, Dana $7 xx0231152
700    1_
$a Kuklínek, Pavel $7 xx0000490
700    1_
$a Meluzínová, Hana $7 xx0062326
700    1_
$a Matějovská Kubešová, Hana, $d 1957- $7 nlk20000083650
700    1_
$a Čejková, P
700    1#
$a Bielaková, Katarína. $7 xx0230571
700    1_
$a Černá, M
773    0_
$w MED00179769 $t Advances in gerontology Uspekhi gerontologii Rossiĭskai͡a akademii͡a nauk, Gerontologicheskoe obshchestvo $x 1561-9125 $g Roč. 24, č. 2 (2011), s. 312-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21957594 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20200318180013 $b ABA008
999    __
$a ok $b bmc $g 950076 $s 785380
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 24 $c 2 $d 312-8 $i 1561-9125 $m Advances in gerontology $n Adv Gerontol $x MED00179769
LZP    __
$a Pubmed-20120817/11/04

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace